These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

495 related items for PubMed ID: 11497229

  • 1. Rationale for non-platinum chemotherapy in advanced NSCLC.
    Murren JR.
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):29-34. PubMed ID: 11497229
    [Abstract] [Full Text] [Related]

  • 2. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N.
    Health Technol Assess; 2001 Jul; 5(32):1-195. PubMed ID: 12065068
    [Abstract] [Full Text] [Related]

  • 3. Chemotherapy in metastatic non-small-cell lung cancer.
    Sandler A.
    Oncology (Williston Park); 2000 Jul; 14(7 Suppl 5):15-27. PubMed ID: 10981287
    [Abstract] [Full Text] [Related]

  • 4. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
    Bunn PA, Kelly K.
    Clin Cancer Res; 1998 May; 4(5):1087-100. PubMed ID: 9607565
    [Abstract] [Full Text] [Related]

  • 5. Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?
    Ferrigno D, Buccheri G.
    Lung Cancer; 2000 Aug; 29(2):91-104. PubMed ID: 10963840
    [Abstract] [Full Text] [Related]

  • 6. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
    Clegg A, Scott DA, Hewitson P, Sidhu M, Waugh N.
    Thorax; 2002 Jan; 57(1):20-8. PubMed ID: 11809985
    [Abstract] [Full Text] [Related]

  • 7. Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.
    Rigas JR.
    Semin Oncol; 2001 Jun; 28(3 Suppl 9):15-20. PubMed ID: 11441410
    [Abstract] [Full Text] [Related]

  • 8. Radiosensitization with chemotherapeutic agents.
    Caffo O.
    Lung Cancer; 2001 Dec; 34 Suppl 4():S81-90. PubMed ID: 11742709
    [Abstract] [Full Text] [Related]

  • 9. [New promising anticancer drugs for lung cancer].
    Ariyoshi Y, Sugiura T.
    Gan To Kagaku Ryoho; 1994 Nov; 21(15):2578-84. PubMed ID: 7979416
    [Abstract] [Full Text] [Related]

  • 10. [Developed new agents for lung cancer].
    Kato Y, Saijo N.
    Nihon Geka Gakkai Zasshi; 2002 Feb; 103(2):218-23. PubMed ID: 11904983
    [Abstract] [Full Text] [Related]

  • 11. New chemotherapeutic agents for non-small cell lung cancer.
    Miller VA, Rigas JR, Grant SC, Pisters KM, Kris MG.
    Chest; 1995 Jun; 107(6 Suppl):306S-311S. PubMed ID: 7781411
    [Abstract] [Full Text] [Related]

  • 12. [New therapeutic approaches in non-small-cell lung carcinoma (NSCLC), stages IV].
    Mavroudis D.
    Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S42-5. PubMed ID: 11924243
    [No Abstract] [Full Text] [Related]

  • 13. Promising new agents in the treatment of non-small cell lung cancer.
    Edelman MJ, Gandara DR.
    Cancer Chemother Pharmacol; 1996 Nov; 37(5):385-93. PubMed ID: 8599859
    [Abstract] [Full Text] [Related]

  • 14. Chemotherapy for non-small cell lung cancer: have we reached a new plateau?
    Shepherd FA.
    Semin Oncol; 1999 Feb; 26(1 Suppl 4):3-11. PubMed ID: 10201515
    [Abstract] [Full Text] [Related]

  • 15. Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy.
    Khuri FR.
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):53-62. PubMed ID: 12108898
    [Abstract] [Full Text] [Related]

  • 16. Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative.
    Cappuzzo F, Rocha Lima CM, Sherman CA, Green MR.
    Oncology (Williston Park); 2000 Jul; 14(7 Suppl 4):7-14. PubMed ID: 10960939
    [Abstract] [Full Text] [Related]

  • 17. Phase II and III studies with new drugs for non-small cell lung cancer: a systematic review of the literature with a methodology quality assessment.
    Meert AP, Berghmans T, Branle F, Lemaître F, Mascaux C, Rubesova E, Vermylen P, Paesmans M, Sculier JP.
    Anticancer Res; 1999 Jul; 19(5C):4379-90. PubMed ID: 10650780
    [Abstract] [Full Text] [Related]

  • 18. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
    Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
    [Abstract] [Full Text] [Related]

  • 19. New agents in the treatment of small cell lung cancer.
    Ghaemmaghami M, Jett JR.
    Chest; 1998 Jan; 113(1 Suppl):86S-91S. PubMed ID: 9438696
    [Abstract] [Full Text] [Related]

  • 20. New chemotherapeutic agents for the treatment of non-small cell lung cancer: the Japanese experience.
    Saijo N.
    Chest; 1998 Jan; 113(1 Suppl):17S-23S. PubMed ID: 9438685
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.